Division of Neonatal-Perinatal Medicine, Department of Pediatrics, Saint Louis University School of Medicine, Cardinal Glennon Children's Hospital, St. Louis, MO, USA.
Division of Neonatology, Department of Obstetrics and Gynecology, University of Tennessee Medical Center, Knoxville, TN, USA.
J Perinatol. 2021 Jul;41(7):1681-1689. doi: 10.1038/s41372-021-01066-x. Epub 2021 May 13.
The addition of budesonide to surfactant in very-low-birth-weight infants with less severe RDS decreased bronchopulmonary dysplasia (BPD) severity. Long-term neurodevelopmental follow-up was needed to monitor for systemic effects of budesonide.
Infants ≤1250 g who received intratracheal budesonide (0.25 mg/kg) with surfactant (n = 173) were compared to a historical cohort who received surfactant alone (n = 294). Peabody Developmental Motor Scales II at 4-6 months corrected age and Bayley Scales of Infant & Toddler Development III at 18-22 months corrected age were compared.
There were no differences in muscle tone or motor skills by Peabody exam. There were no differences in the cognitive, language, or motor domains between cohorts on Bayley III.
In a cohort of infants treated with budesonide mixed with surfactant, there were no differences in developmental outcomes at 4-6 months or 18-22 months corrected age.
在患有较轻 RDS 的极低出生体重儿中，将布地奈德与表面活性剂联合使用可降低支气管肺发育不良（BPD）的严重程度。需要进行长期的神经发育随访以监测布地奈德的全身作用。
接受气管内布地奈德（0.25mg/kg）联合表面活性剂治疗的（n=173）患儿与仅接受表面活性剂治疗的历史队列（n=294）进行比较。比较两组患儿在 4-6 个月校正年龄时的 Peabody 发育运动量表第二版和在 18-22 个月校正年龄时的贝利婴幼儿发育量表第三版的评估结果。
两组患儿在 Peabody 检查中肌肉张力或运动技能方面没有差异。两组患儿在贝利婴幼儿发育量表第三版的认知、语言或运动领域均无差异。
在接受布地奈德联合表面活性剂治疗的患儿队列中，在 4-6 个月或 18-22 个月校正年龄时，发育结局没有差异。
